Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer gene therapies - Anchiano Therapeutics

Drug Profile

Research programme: cancer gene therapies - Anchiano Therapeutics

Alternative Names: BC-820; BC-821; BC-822; H19-DTA+TNF; IGF2-DTA

Latest Information Update: 30 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioCancell Therapeutics
  • Developer Anchiano Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 27 Aug 2018 BioCanCell Therapeutics is now called Anchiano Therapeutics
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Israel (Parenteral, Injection)
  • 06 Nov 2015 BioCancell cover patents for BC 821 in USA, Japan, Europe, Russia, China, Australia and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top